Table 3.
Adverse events experienced by both groups at baseline and at week 24. Scale: 4 = severe, 3 = Moderate, 2 = Mild, 1 = slight, 0 = absent; aFisher’s exact test
| Adverse events | Groups | At baseline | At week 24 | ||||
|---|---|---|---|---|---|---|---|
| Total n (%) | Mean | P (2-tailed) | Total n (%) | Mean | P (2-tailed) | ||
| Dry Mouth | Dual user Sole EC user |
82 (55.4) 30 (42.9) |
1.229 0.900 |
0.062 | 21 (16.5) 09 (14.5) |
.2205 .2097 |
0.904 |
| Sore throat | Dual user Sole EC user |
32 (21.6) 9 (12.9) |
.3986 .2714 |
0.262 | 13 (10.2) 8 (12.9) |
.1102 .1290 |
0.720 |
| Cough | Dual user Sole EC user |
34 (23) 8 (11.4) |
0.5473 0.1571 |
< 0.001 | 31 (24.4) 7 (11.3) |
.3858 .1452 |
0.009 |
| Anxiety | Dual user Sole EC user |
0 (0) 1 (1.4) |
.0000 .0286 |
0.321 | – | – | – |
| Stomach disturbances | Dual user Sole EC user |
2 (1.4) 0 (0) |
.0270 .0000 |
0.158 | – | – | – |
| Nausea | Dual user Sole EC user |
– | – | – | 6 (4.7) 2 (3.2) |
.0551 .0323 |
0.535 |
| Vomiting | Dual user Sole EC user |
0 (0) 5 (7.1) |
0.000 0.1571 |
0.033 | 3 (2.4) 2 (3.2) |
.0394 .0484 |
0.830 |
| Headache | Dual user Sole EC user |
14 (9.5) 6 (9.2) |
.1486 .1286 |
0.771 | 5 (3.9) 5 (8.1) |
.0551 .0968 |
0.388 |
| Breathing Problem |
Dual user Sole EC user |
27 (18.8) 2 (2.8) |
.3243 0429 |
< 0.001 | 24 (18.9) 4 (6.5) |
.2598 .0806 |
0.008 |
| Other (fever, gums bleeding | Dual user Sole EC user |
0 (0) 3 (4.3)a |
.0000 .0571 |
0.103 | 1 (0.8) 2 (3.2)b |
.1102 .0806 |
0.775 |
aFever cases; bGum bleeding
Independent t-test was applied to compare the mean differences between the groups